Swedish Orphan Biovitrum AB: Sobi Publishes Its Report For The Third Quarter 2016, Raises Guidance
STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Swedish Orphan Biovitrum AB (publ) (Sobi™)(STO:SOBI) today announces its results for the third quarter 2016. Revenue for the quarter totalled SEK 1,171 M (786), an increase of 49 per cent compared to previous year. Based on strong performance across the portfolio and an earlier launch for Alprolix, the company has raised guidance for the full year.
Swedish Orphan Biovitrum AB (publ) (Sobi™)(STO:SOBI) today announces its results for the third quarter 2016. Revenue for the quarter totalled SEK 1,171 M (786), an increase of 49 per cent compared to previous year. Based on strong performance across the portfolio and an earlier launch for Alprolix, the company has raised guidance for the full year.